{"classes":[{"categories":[{"measurements":[{"comment":"below the level of detection","groupId":"OG000","lowerLimit":"10.12","upperLimit":"NA","value":"16.95"},{"groupId":"OG001","lowerLimit":"10.64","upperLimit":"18.73","value":"13.67"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"description":"Kaplan-Meier methods will be used to summarize OS. Hazard ratios for OS will be presented using point estimates and 95% confidence intervals.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive docetaxel IV over 1 hour and cisplatin IV over 2 hours or carboplatin IV over 2 hours on day 1 and erlotinib hydrochloride PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue erlotinib hydrochloride treatment.","id":"OG000","title":"Arm A (Combination Chemotherapy and Erlotinib Hydrochloride)"},{"description":"Patients receive docetaxel and cisplatin or carboplatin as in Arm I and placebo PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue placebo treatment.","id":"OG001","title":"Arm B (Combination Chemotherapy and Placebo)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"5 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}